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Summary
Single nucleotide polymorphisms (SNPs) in the vitamin D pathway genes have been implicated in 
cutaneous melanoma (CM) risk, but their role in CM disease-specific survival (DSS) remains 
obscure. We conducted comprehensively survival analysis of 2,669 common SNPs in the vitamin 
D pathway using data from a published genome-wide association study (GWAS) at The University 
of Texas M.D. Anderson Cancer Center (MDACC), followed by a replication GWAS from the 
Nurses’ Health Study and Health Professionals Follow-up Study. Among the 2,669 SNPs, 203 
were significantly associated with DSS in MDACC dataset (P<0.05 and false positive report 
probability<0.2), of which 18 were the tag SNPs. In the replication, 2 of these 18 SNPs showed 
nominal significance: the VDBP rs12512631 T>C was associated with a better DSS [combined 
hazards ratio (HR)=0.66]; and the same for RXRA rs7850212 C>A (combined HR=0.38). Further 
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bioinformatics analyses indicated that these loci may modulate corresponding gene methylation 
status.
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cutaneous melanoma; vitamin D pathway; disease specific survival; single nucleotide 
polymorphisms; Cox regression
Introduction
Vitamin D is a fat-soluble steroid hormone, 25(OH)D3 is the most accepted measure of the 
body stores of vitamin D, and 1α,25(OH)2D3 is an active metabolite of vitamin D (Holick, 
1996). The first step in the vitamin D synthesis is the formation of vitamin D3 in the skin 
through stimulation by ultraviolet irradiation. Endogenous or dietary vitamin D3 is 
hydroxylated by 25OHase (encoded by CYP27A1) to 25(OH)D3 in the liver and then 1α-
hydroxylated via 1α-OHase (encoded by CYP27B1) to 1α,25(OH)2D3 in the kidney. The 
24-hydroxylation of 25(OH)D3 and 1α,25(OH)2D3 by 24OHase (encoded by CYP24A1) is 
the rate-limiting step for the vitamin D catabolism (Hewison et al., 2000). The vitamin D-
binding protein (DBP) encoded by the VDBP gene facilitates vitamin D actions by carrying 
vitamin D metabolites to various sites of action, and polymorphic DBP proteins differ in 
their affinity for 1,25(OH)2D (Pani et al., 2002). Classical action of 1α,25(OH)2D3 is 
mediated by the binding of vitamin D receptor (VDR)-9-cis-retinoid X receptor (RXR) 
complex at the vitamin-D response elements (VDREs), resulting in activation of gene 
expression of specific target genes (Carlberg et al., 1993). Vitamin D may inhibit the MAPK 
signaling by suppressing the epidermal growth factor receptor (EGFR) pathway and insulin-
like growth factor, but it may also promote apoptosis via the IGFR1/PI3K-Akt signaling 
pathway and by inhibiting telomerase (Deeb et al., 2007). Overall, vitamin D exerts 
pleiotropic effects in regulating cell proliferation, growth modulation, differentiation, 
apoptosis and immune modulation, which have an influence on both carcinogenesis of 
normal cells and metastatic potential of cancer cells (Deeb et al., 2007).
There is a myriad of epidemiological evidence associating vitamin D with mortality rates of 
several cancers (Chowdhury et al., 2014). For example, higher vitamin D levels were found 
to be associated with a lower risk of death in patients with colorectal cancer (Ng et al., 
2008), prostate cancer (Tretli et al., 2009), and non-small cell lung cancer with stage IB/IIB 
(Zhou et al., 2007), while a deficient vitamin D status in patients with early breast cancer 
was associated with a worse disease-free survival, compared with those with an adequate 
vitamin D status (Goodwin et al., 2009). Preclinical studies also suggested that 1α,
25(OH)2D3 potentiates anticancer activity of some chemotherapeutic agents (Hershberger et 
al., 2002), and attempts have been made to translate these findings to clinical application of 
1α,25(OH)2D3 across several tumor types (Fakih et al., 2007; Lappe et al., 2007; 
Wactawski-Wende et al., 2006).
Tumor Breslow thickness remains the most important single prognostic factor for patients 
with cutaneous melanoma (CM) (Balch et al., 2009). In general, CM patients with thin 
tumors have a much longer survival than those with thick tumors (Balch et al., 2009). Serum 
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vitamin D levels have been tested as a potential modifier of CM prognosis associated with 
Breslow thickness. For example, in 1043 cases from the first Leeds case-control study of 
CM, a single estimation of serum vitamin D level taken at recruitment was inversely 
correlated with Breslow thickness (Randerson-Moor et al., 2009). In another study of 271 
patients with CM, higher vitamin D levels were found to be associated with lower Breslow 
thickness at diagnosis and were positively associated with relapse and death (Newton-
Bishop et al., 2009). A subsequent small study in patients with stage IV CM reported that 
lower vitamin D levels were associated with poorer survival (Nurnberg et al., 2009). A more 
recent study of CM patients in Germany revealed that lower 25(OH)D levels were 
significantly associated with greater Breslow thickness and later disease stages (Gambichler 
et al., 2013).
Data on the role of single nucleus polymorphisms (SNPs) in the vitamin D pathway genes in 
CM outcome are sparse (Davies et al., 2014; Hutchinson et al., 2000; Santonocito et al., 
2007; Schafer et al., 2012). Most of the studies used Breslow thickness as a proxy of 
survival, and the results have been conflicting. In addition, only a handful of SNPs have 
generally been assessed, as identified by the tagging SNPs in certain genes. Finally, most 
studies have been performed in single hospital or cancer center, and frequently lack either 
the scientific rigor or the external validity required to account for widespread changes in 
practice. To the best of our knowledge, a systematic, multicenter evaluation of genetic 
variants of vitamin D-related genes and CM specific survival is still lacking. In the present 
study, to identify prognostic SNPs in the vitamin D pathway, we conducted Cox proportional 
hazards regression analyses in a previously published large genome-wide association study 
(GWAS) dataset conducted at the University of M.D. Anderson Cancer Center (MDACC), 
and subsequently validate the significant SNPs in another GWAS dataset from Harvard 
University (Amos et al., 2011; Song et al., 2012). Both of these GWASs had available long-
term follow-up data. We comprehensively evaluated whether the selected SNPs in 
CYP24A1, CYP27A1, CYP27B1, CYP2R1, VDR, VDBP, RXRA, RXRB, RXRG, NCOA1, 
NCOA2, NCOA3, NCOR1 and SNW1 contribute to disease specific survival (DSS) in CM 
patients. These 14 genes were selected based on their biological roles in the vitamin D 
metabolism and signaling in cancer (Deeb et al., 2007).
Results
Study populations
Overall, 858 patients from MDACC and 409 patients from Harvard University were included 
in the analyses (Table 1). All patients with primary CM were non-Hispanic white. Harvard 
patients had a relatively longer median follow-up time (MFT, 179 months) as compared with 
MDACC patients (81 months). During the follow-up, there were 95 (11.1%) and 48 (11.5%) 
patients who died of CM in MDACC and Harvard patients, respectively. Mean ages of 
MDACC and Harvard patients were 52.4 and 60.1 years old, respectively.
Survival-analysis
In the discovery analysis of the MDACC dataset for 2,669 SNPs that passed strict quality 
control measures, we found that 203 SNPs met our selection criteria (i.e., FPRP<0.2; among 
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them, 81 with P< 10−3). As shown in Supplementary Table 1, these 203 SNPs included 111 
SNPs of CYP27A1, six of VDBP, two of NCOA3, 20 of RXRA, 61 of RXRG, three of 
SNW1. Next, with r2>0.6 between SNPs in the same gene as the cut-off value, 18 SNPs 
were chosen as the tagging SNPs (Table 2 and Supplementary Figure 1).
Subsequently, the significant association between the 18 tagging SNPs and CM DSS were 
validated in the CM patient population from Harvard University following the same 
eligibility criteria as used in the discovery population. As summarized in Table 2, under an 
additive model, two SNPs were statistically significantly associated with DSS and had the 
same direction of effects with the MDACC dataset. One SNP was located in the VDBP gene, 
while the other was mapped to the RXRA gene (VDBP rs12512631 T>C and RXRA 
rs7850212 C>A).
Pooling data from each of the datasets, we derived the joint HR and 95%CI under a 
conservative random-effects model for each SNP and the associated per-allele P values. As 
shown in Table 2 for detailed results of the survival analysis, VDBP rs12512631 (T>C) was 
associated with a better DSS in both MDACC and Harvard datasets, with an HR of 0.70 and 
0.58, respectively. Similarly, the A allele of rs7850212 C>A was associated a decreased risk 
of death (HR = 0.41 in MDACC patients and HR = 0.31 in Harvard patients). As shown in 
Figure 2 with the Kaplan-Meier curves, patients with the VDBP rs12512631 TT genotype 
had a poorer survival compared with those with TC and CC genotypes; likewise, the 
rs7850212 CC genotype was also associated with an unfavorable DSS. In the meta-analysis, 
none of the effects of the two SNPs were significantly heterogeneous among the studies 
(rs12512631, Pheterogeneity = 0.516; and rs7850212, Pheterogeneity = 0.676). The VDBP 
rs12512631 C allele was significantly associated with the survival of CM patients (HR=0.66, 
95%CI= 0.51 – 0.86, P = 1.88×10−3). For RXRA rs7850212, there was a significant 
association between the variant allele A and a better DSS (HR= 0.38, 95%CI = 0.22–0.68, P 
= 9.54×10−4). Additionally, we also combined the HRs and 95%CIs without any adjustment, 
and the results were similar with those with the adjustment (Supplementary Figure 2).
In silica functional validation
To further understand how the germline genetic variation influences the vitamin D pathway 
in tumor progress, we examined meQTL associations in the Multiple Tissue Human 
Expression Resource (MuTHER) project. As shown in Figure 3, there was evidence for 
some cismeQTL effects, including rs12512631 (VDBP, probe ID = cg04837494, P = 
3.80×10−5) and rs7850212 (RXRA, probe ID cg13510651, P = 2.14×10−8). In detail, the 
variant alleles of these two SNPs were associated with methylation status of corresponding 
genes, and then potentially affect gene transcription and phenotypic variation.
Discussion
In the present study, we comprehensively evaluated the effects of SNPs from some major 
vitamin D-related genes on DSS of CM patients. We identified that two SNPs in VDBP and 
RXRA genes were protective and prolonged CM DSS across two different GWAS datasets. 
These results are biologically plausible and supported by previous experimental studies. For 
example, vitamin D has been reported to inhibit growth of malignant melanocytes both in 
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vitro and in vivo (Colston et al., 1981). Additionally, vitamin D was also identified as 
inducing differentiation (Danielsson et al., 1998) and inhibiting invasiveness (Yudoh et al., 
1999) in melanoma cell lines. Other in vivo trials found that vitamin D can suppress 
melanoma proliferation and inhibit metastasis in immune suppressed rodents (Eisman et al., 
1987; Yudoh et al., 1999). Similarly, in the laboratory-based trials, 1,25(OH)2D molecule 
was shown to induce apoptosis in human melanoma cell lines in vitro (Seifert et al., 2004).
In the present study, VDBP rs12512631 and RXRA rs7850212 were found to be associated 
with CM survival; in addition, these two SNPs were associated with the methylation status 
of their corresponding genes. There is an existing evidence that VDBP may contribute to the 
variation of serum vitamin D levels in healthy populations (Biernacka et al., 2009; Bu et al., 
2010; Wacholder et al., 2004) and cancer patients (Laddha et al., 2014). In Prostate, Lung, 
Colorectal and Ovarian Cancer Screening Trial performed in 2009, 150 control participants 
were randomly selected and associations between Vitamin D-related genes and serum 
vitamin D concentrations were tested; the results showed that rs12512631 was associated 
with modest differences in serum 25(OH)D (Laddha et al., 2014). Meanwhile, rs12512631 
was statistically significantly associated with serum 25(OH)D concentrations in healthy 
Danish children and adults (Pani et al., 2002). A similar result was also found in the subset 
of 404 individuals with colorectal adenomas from the Ursodeoxycholic Acidtrial (Song et 
al., 2012). Therefore, it is likely that rs12512631 may modulate the risk of death by affecting 
corresponding gene’s function or the vitamin D level, providing a biological basis for the 
observed associations. The evidence for the role of rs7850212 of RXRA in CM survival is 
relatively rare. However, there was a report that RXRA SNPs were associated with poorer 
disease-free survival in breast cancer patients (Pande et al., 2013); additionally, a gene-level 
association was observed for RXRA and colon adenoma recurrence (Egan et al., 2010). 
Meanwhile, the representative tagging SNPs are also associated with corresponding gene 
methylation status, providing an additional biological support.
In the literature, some VDR SNPs (e.g., Apa1 rs7975232, Fok1 rs2228570, Bsm1 
rs1544410, and Taq1 rs731236) are the vitamin D-related SNPs that have been mostly 
studied for an association with CM prognosis (Hutchinson et al., 2000; Santonocito et al., 
2007; Schafer et al., 2012); however, the reported results have been inconclusive. For 
example, it was reported that Taq1 rs731236 and Fok1 rs2228570 were associated with 
Breslow thickness (Hutchinson et al., 2000). However, in another study of 101 CM patients, 
a significant association between Bsm1 rs1544410 and Breslow thickness was found, but not 
for the Fok1 rs2228570 (Santonocito et al., 2007), Taq1 rs731236 and Apa1 rs7975232 
(Schafer et al., 2012). In the present study, we found that Apa1 rs7975232 and Bsm1 
rs1544410 were marginally associated with MSS with P values of 0.045 and 0.043 in the 
MDACC dataset, respectively, which did not reach the significant threshold in the Harvard 
dataset (P values of 0.481 and 0.452, respectively). The discrepancies between the results of 
these GWAS studies may attribute to differences in populations recruited as well as study 
sizes and designs; especially we used melanoma-specific survival instead of Breslow 
thickness. Meanwhile, the VDBP rs2282679 genotype, the strongest genetic determinant of 
serum vitamin D levels reported in a previous GWAS study (Wang et al., 2010), was not 
significantly associated with CM survival in the MDACC dataset (P = 0.852), which is 
consistent with the report of Davies et al. (Davies et al., 2014). Similarly, in the breast cancer 
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study reported by Mala et al., the association of rs2282679 with survival did not reach the 
threshold of significance (Pande et al., 2013).
The major strength of the present study is that we used DSS as the end point for CM 
outcomes. Although Breslow thickness works well in predicting CM prognosis and overall 
survival is similar to DSS in most cases, DSS is the most clinically critical outcome 
measurement for CM survival analyses. Moreover, a pathway-based analysis, rather than 
single-gene or single-SNP studies, can assist in identifying biologically meaningful 
prognostic SNPs from the available high-dimensional data and also can improve detection of 
the combined effects of these SNPs on survival.
One short coming of the present study is that serum vitamin D levels were not measured 
because only the historical data were made available to us for the analysis. Another potential 
limitation could be the differences in tumor characteristics or treatment regimens between 
the two study sites (i.e., MDACC and Harvard University), which might confound specific 
survival differences. To minimize the effect, we combined the results using the conservative 
random-effects model. It should be noted that we used less stringent FPRP method instead 
of false discovery rate (Benjamini and Yekutieli, 2001) or Bonferroni correction (Bland and 
Altman, 1995) to control for multiple comparisons in the discovery MDACC dataset. 
Although this may lead to higher probability of false positive, considering the consistent 
effects of those identified SNPs between the discovery and validation datasets, and their 
potential functions in regulating gene methylation, it is less likely that our findings are due 
to false discovery.
In conclusion, our meta-analysis suggests a role of VDBP rs12512631 T>C and RXRA 
rs7850212 C>A in CM DSS as assessed in two independent GWAS datasets. Considering 
the important role of vitamin D throughout the cancer continuum, these genetic variants may 
represent promising prognostic biomarkers in decision making for CM clinical management.
Materials & Methods
Study populations and genotyping
MDACC GWAS dataset—The MDACC CM GWAS has been previously reported (Amos 
et al., 2011). The characteristic details of the patient subjects in the survival analysis have 
also been recently described (Yin et al., 2014; Yuan et al., 2015; Zhang et al., 2015). Briefly, 
the present study included 858 histologically confirmed CM patients who were non-
Hispanic white, had complete information for selected prognostic variables and were 
enrolled at MDACC between March 1998 and August 2008. For each of the patients, a DNA 
sample was extracted from the whole blood, and demographic, prospective clinical and 
pathological data were collected from a standard life-style questionnaire and/or extracted 
from patient medical charts. Tumor stages were classified according to the American Joint 
Committee on Cancer (AJCC) for the melanoma staging system (Balch et al., 2009). The 
follow-up was conducted using the standardized guidelines (Gershenwald and Ross, 2011). 
Stage of the disease and length of the follow-up were determined from the date of diagnosis. 
All individuals provided a written informed consent under an Institutional Review Board-
approved protocol.
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The genotype data in the present study can be accessed by using the National Center for 
Biotechnology Information (NCBI) Database of Genotypes and Phenotypes (dbGaP; http://
www.ncbi.nlm.nih.gov/gap), with the study accession number phs000187.v1.p1 (Mailman et 
al., 2007; Tryka et al., 2014). Briefly, the genomic DNA extracted from the whole blood was 
genotyped with the Illumina HumanOmni-Quad_v1_0_B array, and the genotypes were 
called using the BeadStudio algorithmat the John Hopkins University Center for Inherited 
Disease Research (CIDR). The detailed genotyping information and data quality control can 
be found in the previously described GWAS (Amos et al., 2011). Genome-wide imputation 
was performed by using the MACH software based on the 1000 Genomes project, phase I 
V2 CEU data (Li et al., 2010), in which around 6.78 SNPs were included, after the quality 
control, if they had a minor allele frequency ≥ 0.05, genotyping rate ≥ 95%, Hardy-Weinberg 
equilibrium p-value ≥ 0.00001, or imputation r2 ≥ 0.8.
Harvard GWAS dataset—The Harvard CM GWAS dataset consisted of two studies: 
Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS). Sampling, 
genotyping and quality control procedures have been described previously (Song et al., 
2012). In brief, eligible cases in both the NHS and HPFS cohorts were participants with 
histopathologically confirmed invasive melanoma, diagnosed at any time after baseline up to 
the 2008 follow-up cycle for both cohorts. All subjects were US non-Hispanic white.
Genotyping was performed using the Illumina HumanHap610 array. Based on the genotyped 
SNPs and haplotype information from the 1000 Genomes Project [Utah Residents with 
Northern and Western European Ancestry (CEU) data, phase I v3, March 2012), genotypes 
for over 5.5 million SNPs were imputed using the program MACH (Biernacka et al., 2009). 
Only SNPs with imputation quality r2 ≥ 0.8 and minor allele frequency ≥ 0.05 in each study 
were used in the final analysis. In the final analysis, only 409 patients were kept in the data 
after quality control.
Gene and SNP selection
We selected variants of 14 genes in the vitamin D pathway based on their roles in the 
vitamin D metabolism and signaling in cancer (Deeb et al., 2007): CYP24A1, CYP27A1, 
CYP27B1, CYP2R1, VDR, VDBP, RXRA, RXRB, RXRG, NCOA1, NCOA2, NCOA3, 
NCOR1 and SNW1. Genotyped or imputed common SNPs within these genes or their ± 20-
kb flanking regions were extracted. As a result, 2,669 (428 genotyped or 2241 imputed) 
common SNPs in the vitamin D pathway were extracted from the MDACC GWAS dataset.
Statistical methods
In the follow-up, causes of death other than CM were considered censored. We assessed an 
additive genetic model for each SNP in the MDACC discovery dataset by multivariable Cox 
proportional hazards regression analysis by using GenABEL package of R software 
(Aulchenko et al., 2007); the adjusted variables included age at diagnosis, sex, clinical stage, 
Breslow thickness, Clark level and ulceration of tumor in the MDACC dataset. False positive 
report probability (FPRP) was calculated to assess the false-positive association findings 
(Wacholder et al., 2004). For all the significant results, we assigned a prior probability of 0.1 
to detect a HR of 1.5 for an association with genotypes and alleles of each SNP. Only those 
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results with an FPRP value < 0.2 were considered as a noteworthy association (Wacholder et 
al., 2004). Kaplan-Meier survival curves and log-rank tests were used to evaluate the effects 
of genetic variants on the cumulative probability of death (Kaplan and Meier, 1958). For 
SNPs showing statistically significant differences in DSS with an FPRP vale <0.2 in the 
discovery, we selected the tagging SNPs based on pairwise r2>0.6, using LD information 
from the latest 1000 Genomes Project for CEU populations (Genomes Project et al., 2012). 
Next, the prognostic roles of tagging SNPs were validated in the Harvard GWAS dataset, 
with adjustment for age at diagnosis and sex in multivariable Cox analysis. Pooled hazards 
ratios (HRs) and 95% confidence intervals (95%CIs) were calculated for the meta-analysis 
using a conservative random-effects model, and inter-study heterogeneity was assessed with 
Cochrane’s Q test. Finally, the methylation quantitative trait loci (meQTL) association was 
assessed by Genevar on adipose tissue from a population of 428 female twin-pairs (856 
individuals), collected as a part of the MuTHER Project and publically available (Grundberg 
et al., 2012).
All statistical analyses were carried out by R software (version 3.0.2; The R Foundation for 
Statistical Computing, Vienna, Austria), Stata v14.0 (Stata College, Texas, US) and 
Statistical Analysis System software (version 9.1.3; SAS Institute, Cary, NC, USA). Figure 1 
provides the flow chart, illustrating procedures of analyses in this study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
Our study suggests a role of VDBPrs12512631 T>C and RXRA rs7850212 C>A in CM 
DSS as assessed in two independent GWAS datasets. Considering the important role of 
vitamin D throughout the cancer continuum, these genetic variants may represent 
promising prognostic biomarkers in decision making for CM clinical management.
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Figure 1. 
Flow chart of this study.
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Figure 2. 
Kaplan-Meier plots of specific survival of CM patients with different genotypes of 
rs12512631 (panel A, B) and rs7850212 (panel C, D).
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Figure 3. 
meQTL associations of VDBP rs12512631 (panel A), RXRA rs7850212 (panel B) with 
corresponding genes. The meQTL associations was assessed by Genevar on adipose tissue 
from a population of 428 female twin-pairs (856 individuals), collected as a part of the 
MuTHER Project.
Yin et al. Page 16
Pigment Cell Melanoma Res. Author manuscript; available in PMC 2017 January 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Yin et al. Page 17
Ta
bl
e 
1
Ch
ar
ac
te
ris
tic
s o
f t
he
 st
ud
y 
po
pu
la
tio
ns
 a
t t
he
 ti
m
e 
of
 a
na
ly
sis
.
Pa
ra
m
et
er
M
D
AC
C
H
ar
v
a
rd
Pa
tie
nt
s
D
ea
th
 (%
)
M
FT
H
R
 (9
5%
CI
)*
P*
Pa
tie
nt
s
D
ea
th
 (%
)
M
FT
H
R
 (9
5%
CI
)*
P*
To
ta
l
85
8
95
 (1
1.1
)
81
.0
40
9
48
 (1
1.5
)
17
9.
0
A
ge
 (y
ea
rs 
old
)
 
≤5
0
37
1
31
 (8
.4)
85
.8
1.
00
72
3 
(4.
2)
35
2.
5
1.
00
 
>
50
48
7
64
 (1
3.1
)
78
.1
1.
69
 (1
.10
 – 
2.5
9)
0.
01
7
33
7
45
 (1
3.4
)
16
7.
0
4.
04
 (1
.25
 – 
13
.06
)
0.
02
0
Se
x
 
M
al
e
49
6
69
 (1
3.9
)
77
.8
1.
00
13
8
17
 (1
2.3
)
19
8.
0
1.
00
 
Fe
m
al
e
36
2
26
 (7
.2)
85
.9
0.
48
 (0
.31
 – 
0.7
6)
0.
00
2
27
1
31
 (1
1.4
)
15
5.
5
1.
16
 (0
.64
 – 
2.1
0)
0.
62
2
M
D
A
CC
 =
 M
D
 A
nd
er
so
n 
Ca
nc
er
 C
en
te
r, 
M
FT
 =
 m
ed
ia
n 
fo
llo
w
-u
p 
tim
e 
(m
on
ths
);
*
u
n
iv
ar
ia
te
 a
na
ly
sis
.
Pigment Cell Melanoma Res. Author manuscript; available in PMC 2017 January 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Yin et al. Page 18
Ta
bl
e 
2
Su
rv
iv
al
 re
su
lts
 o
f 1
8 
ta
g 
SN
Ps
 (r
-
sq
ua
re
 >
0.
6) 
wi
th 
FP
RP
 < 
0.2
 in
 th
e M
DA
CC
 d
at
as
et
 a
nd
 th
ei
r r
ep
lic
at
io
n 
in
 th
e 
H
ar
va
rd
 d
at
as
et
.
SN
P
G
en
e
C
hr
EA
M
D
AC
C
H
ar
v
a
rd
M
et
a
M
A
F
H
R
 (9
5%
CI
)
P*
FP
R
P
M
A
F
H
R
 (9
5%
CI
)
P*
*
H
R
(95
%
CI
)
P
I2
P h
et
rs
64
26
91
4
RX
RG
1
G
0.
06
2.
04
 (1
.18
 – 
3.5
3)
1.
10
×1
0−
2
0.
17
1
0.
06
0.
82
 (0
.32
–2
.07
)
0.
66
9
1.
40
 (0
.58
 – 
3.3
0)
0.
45
3
63
.6
0
0.
09
9
rs
28
36
95
RX
RG
1
A
0.
45
1.
68
 (1
.24
 – 
2.2
9)
9.
00
×1
0−
4
0.
01
1
0.
44
0.
87
 (0
.57
–1
.31
)
0.
49
2
1.
23
 (0
.65
 – 
2.3
4)
0.
53
4
84
.1
8
0.
01
3
rs
28
54
80
RX
RG
1
G
0.
22
1.
47
 (1
.06
 – 
2.0
4)
2.
05
×1
0−
2
0.
16
5
0.
22
1.
14
 (0
.72
–1
.80
)
0.
58
1
1.
35
 (1
.03
 – 
1.7
6)
0.
02
7
0.
00
0.
37
6
rs
37
67
33
2
RX
RG
1
A
0.
24
0.
59
 (0
.39
 – 
0.8
9)
1.
10
×1
0−
2
0.
12
0
0.
24
0.
91
 (0
.57
–1
.46
)
0.
68
7
0.
72
 (0
.47
 – 
1.1
0)
0.
12
7
46
.2
3
0.
17
5
rs
15
78
61
RX
RG
1
G
0.
21
1.
51
 (1
.09
 – 
2.0
8)
1.
23
×1
0−
2
0.
09
9
0.
19
0.
97
 (0
.59
–1
.60
)
0.
91
4
1.
26
 (0
.83
 – 
1.9
3)
0.
28
5
53
.6
4
0.
14
4
rs
11
50
79
56
0
RX
RG
1
C
0.
16
1.
65
 (1
.18
 – 
2.3
0)
3.
08
×1
0−
3
0.
03
1
0.
14
0.
87
 (0
.48
–1
.58
)
0.
65
4
1.
26
 (0
.68
 – 
2.3
4)
0.
46
7
70
.5
5
0.
06
6
rs
37
53
89
6
RX
RG
1
G
0.
38
1.
58
 (1
.15
 – 
2.1
5)
4.
35
×1
0−
3
0.
03
4
0.
35
0.
88
 (0
.57
–1
.34
)
0.
54
1
1.
20
 (0
.68
 – 
2.1
3)
0.
53
1
78
.9
2
0.
03
0
rs
38
20
36
7
RX
RG
1
G
0.
21
1.
51
 (1
.11
 – 
2.0
4)
7.
95
×1
0−
3
0.
06
3
0.
21
0.
87
 (0
.52
–1
.46
)
0.
59
7
1.
19
 (0
.70
 – 
2.0
4)
0.
51
4
69
.1
9
0.
07
1
rs
21
94
89
9
RX
RG
1
A
0.
37
1.
51
 (1
.13
 – 
2.0
1)
5.
18
×1
0−
3
0.
04
2
0.
34
0.
72
 (0
.46
–1
.14
)
0.
15
9
1.
07
 (0
.52
 – 
2.2
0)
0.
86
3
86
.2
0
0.
00
7
rs
37
53
89
8
RX
RG
1
G
0.
21
1.
44
 (1
.06
 – 
1.9
5)
1.
84
×1
0−
2
0.
14
4
0.
20
0.
84
 (0
.49
–1
.43
)
0.
51
5
1.
15
 (0
.69
 – 
1.9
4)
0.
59
3
66
.1
1
0.
08
6
rs
15
29
38
2
CY
P2
7A
1
2
T
0.
49
1.
70
 (1
.26
 – 
2.3
1)
6.
00
×1
0−
4
0.
00
7
0.
50
1.
25
 (0
.83
–1
.89
)
0.
28
2
1.
50
 (1
.12
 – 
2.0
2)
0.
00
7
28
.8
6
0.
23
8
rs
12
51
26
31
VD
BP
4
C
0.
36
0.
70
 (0
.51
 – 
0.9
5)
2.
41
×
10
−
2
0.
16
8
0.
35
0.
58
 (0
.36
–0
.93
)
0.
02
5
0.
66
 (0
.51
 – 
0.8
6)
1.
88
×1
0−
3
0.
00
0.
51
6
rs
78
50
21
2
RX
RA
9
A
0.
11
0.
41
 (0
.21
 – 
0.7
8)
7.
15
×
10
−
3
0.
17
9
0.
09
0.
31
 (0
.10
–0
.97
)
0.
04
3
0.
38
 (0
.22
 – 
0.6
8)
9.
54
×1
0−
4
0.
00
0.
67
6
rs
67
96
51
44
RX
RA
9
A
0.
12
1.
52
 (1
.07
 – 
2.1
6)
2.
04
×1
0−
2
0.
15
8
0.
13
0.
79
 (0
.43
–1
.48
)
0.
46
9
1.
15
 (0
.61
 – 
2.1
7)
0.
65
6
68
.8
6
0.
07
1
rs
62
57
63
19
RX
RA
9
T
0.
11
1.
71
 (1
.17
 – 
2.4
9)
5.
12
×1
0−
3
0.
05
5
0.
12
1.
00
 (0
.55
–1
.82
)
0.
99
2
1.
38
 (0
.82
 – 
2.3
1)
0.
22
2
54
.5
9
0.
13
7
rs
12
89
56
81
SN
W
1
14
T
0.
32
1.
42
 (1
.06
 – 
1.9
0)
1.
81
×1
0−
2
0.
14
2
0.
35
0.
92
 (0
.59
–1
.43
)
0.
71
9
1.
18
 (0
.78
 – 
1.8
0)
0.
43
9
61
.7
2
0.
10
9
rs
12
89
03
75
SN
W
1
14
G
0.
26
0.
66
 (0
.45
 – 
0.9
5)
2.
45
×1
0−
2
0.
19
7
0.
27
1.
10
 (0
.71
–1
.72
)
0.
66
4
0.
84
 (0
.51
 – 
1.3
9)
0.
49
0
66
.6
8
0.
08
4
rs
77
51
36
85
N
CO
A
3
20
T
0.
21
1.
50
 (1
.07
 – 
2.1
2)
2.
01
×1
0−
2
0.
17
0
0.
21
1.
52
 (0
.98
–2
.35
)
0.
06
1
1.
51
 (1
.15
 – 
1.9
7)
0.
00
3
0.
00
0.
96
3
EA
 =
 e
ffe
ct
 a
lle
le
; M
A
F=
m
in
or
 a
lle
le
 fr
eq
ue
nc
y;
 H
R 
= 
ha
za
rd
s r
at
io
; L
H
R 
= 
lo
w
er
 h
az
ar
ds
 ra
tio
; U
H
R 
= 
up
pe
r h
az
ar
ds
 ra
tio
; F
PR
P 
= 
fa
lse
 p
os
iti
v
e 
re
po
rt 
pr
ob
ab
ili
ty
; P
he
t =
 P
 
he
te
ro
ge
ni
et
y;
A
2 
is 
th
e 
ef
fe
ct
 a
lle
le
;
*
A
dju
ste
d b
y a
ge
, se
x
, 
tu
m
or
 s
ta
ge
, B
re
slo
w
 th
ic
kn
es
s, 
Cl
ar
k 
le
v
el
 a
nd
 u
lc
er
at
io
n 
of
 tu
m
or
;
*
*
A
dju
ste
d b
y a
ge
, se
x
.
Pigment Cell Melanoma Res. Author manuscript; available in PMC 2017 January 29.
